Serous high-grade ovarian carcinoma with a complete loss of SMARCA2 expression.
Staining Pattern in Normal Tissues
Manual protocol
Freshly cut sections should be used (less than 10 days between cutting and staining). Heat-induced antigen retrieval for 5 minutes in an autoclave at 121°C in pH 7,8 Target Retrieval Solution buffer. Apply HMV337 at a dilution of 1:200 at 37°C for 60 minutes. Visualization of bound antibody by the EnVision Kit (Dako, Agilent) according to the manufacturer’s directions.
| Brain | Cerebrum | Strong nuclear SMARCA2 staining of most glia cells while staining is faint or absent in neurons. | |
| Cerebellum | Strong nuclear SMARCA2 staining of most glia cells while staining is lacking in granule cells and in Purkinje cells. | ||
| Endocrine tissues | Thyroid | Nuclear SMARCA2 staining of all cells. | |
| Parathyroid | Nuclear SMARCA2 staining of all cells. | ||
| Adrenal gland | Nuclear SMARCA2 staining of all cells. | ||
| Pituitary gland | In the adenohypophysis the nuclear SMARCA2 staining varies between individual epithelial cells ranging from strongly positive to negative. Most pituicytes show a strong nuclear SMARCA2 staining in the neurohypophysis. | ||
| Respiratory system | Respiratory epithelium | Nuclear SMARCA2 staining of all cells. | |
| Lung | Nuclear SMARCA2 staining of all cells. | ||
| Gastrointestinal tract | Salivary glands | Nuclear SMARCA2 staining of all cells. | |
| Esophagus | Significant decrease of the nuclear SMARCA2 staining from basal/suprabasal to superficial cell layers in the non-keratinizing squamous epithelium. | ||
| Stomach | Nuclear SMARCA2 staining of all cells. The staining is somewhat weaker in glands than in the surface epithelium. | ||
| Duodenum | Nuclear SMARCA2 staining of all cells. | ||
| Small intestine | Nuclear SMARCA2 staining of all cells. | ||
| Appendix | Nuclear SMARCA2 staining of all cells. | ||
| Colon | Nuclear SMARCA2 staining of all cells. | ||
| Rectum | Nuclear SMARCA2 staining of all cells. The staining is somewhat weaker in surface epithelium than in the crypts. | ||
| Liver, Gallbladder, Pancreas | Liver | Nuclear SMARCA2 staining of all cells. Staining is weakest in hepatocytes. | |
| Gallbladder | Nuclear SMARCA2 staining of all cells. | ||
| Pancreas | Nuclear SMARCA2 staining of all cells. | ||
| Genitourinary | Kidney | Nuclear SMARCA2 staining of all cells but SMARCA2 staining is clearly lowest in tubuli. | |
| Urothelium | Nuclear SMARCA2 staining of all cells. | ||
| Male tissues | Prostate | Nuclear SMARCA2 staining of all cells. | |
| Seminal Vesicles | Nuclear SMARCA2 staining of all cells. | ||
| Testis | Nuclear SMARCA2 staining of most cells, but Sertoli cells remain SMARCA2 negative. | ||
| Epididymis | Nuclear SMARCA2 staining of all cells. | ||
| Female tissues | Breast | Nuclear SMARCA2 staining of all cells. | |
| Uterus, myometrium | Nuclear SMARCA2 staining of all cells. | ||
| Uterus, ectocervix | Nuclear SMARCA2 staining of all cells. Slight decrease of the nuclear SMARCA2 staining from basal/suprabasal to superficial cell layers in the non-keratinizing squamous epithelium. | ||
| Uterus, endocervix | Nuclear SMARCA2 staining of all cells. | ||
| Uterus, endometrium | Nuclear SMARCA2 staining of all cells but staining is less intensive in endometrium cells than in stromal cells. | ||
| Fallopian tube | Nuclear SMARCA2 staining of all cells. | ||
| Ovary | Nuclear SMARCA2 staining of all cells. | ||
| Placenta early | Nuclear SMARCA2 staining of all cells. | ||
| Placenta mature | Nuclear SMARCA2 staining of all cells but staining is somewhat reduced in cytotrophoblast cells. | ||
| Amnion | Nuclear SMARCA2 staining of all cells. | ||
| Chorion | Nuclear SMARCA2 staining of all cells. | ||
| Skin | Epidermis | Nuclear SMARCA2 staining of all cells. | |
| Sebaceous glands | Nuclear SMARCA2 staining of all cells. | ||
| Muscle, connective & soft tissues | Heart muscle | Nuclear SMARCA2 staining of all cells. | |
| Skeletal muscle | Nuclear SMARCA2 staining of all cells. | ||
| Smooth muscle | Nuclear SMARCA2 staining of all cells. | ||
| Vessel walls | Nuclear SMARCA2 staining of all cells. | ||
| Fat | Nuclear SMARCA2 staining of all cells. | ||
| Stroma | Nuclear SMARCA2 staining of all cells. | ||
| Endothelium | Nuclear SMARCA2 staining of all cells. | ||
| Bone marrow & lymphoid tissues | Bone marrow | Nuclear SMARCA2 staining of all cells. | |
| Lymph node | Nuclear SMARCA2 staining of all cells. | ||
| Spleen | Nuclear SMARCA2 staining of all cells. | ||
| Thymus | Nuclear SMARCA2 staining of all cells. | ||
| Tonsil | Nuclear SMARCA2 staining of all cells. Slight decrease of the nuclear SMARCA2 staining from basal/suprabasal to superficial cell layers in the non-keratinizing squamous epithelium. | ||
| Remarks | A nuclear staining is seen in all tissues. Some cell types show a reduced expression level. | ||
Details
More product details
More product details
Biology behind
SMARCA2 (SWI/SNF‐related matrix‐associated actin‐dependent regulator of chromatin subfamily A member 2) is coded by the SMARCA2 gene located at chromosome 9p24.3. Along with SMARCA4, SMARCA2 is one of two mutually exclusive, exchangeable DNA-dependent ATPases, which constitute the enzymatic motor of a polymorphic family of SWI/SNF complexes which also include 8–15 further subunits (). SWI/SNF can modify the transcription of genes by altering the chromatin structure surrounding them. SMARCA2 is ubiquitously expressed in the nuclei of normal cells. Mutations in individual members of the SWI/SNF family together represent one of the most common genetic alterations in cancer, observed in about 20% of cases. According to public databases, mutations of SMARCA2 are rare but SMARCA2 downregulation in cancer can occur due to alternative mechanisms. Targeting SMARCA2 may cause synthetic lethality in SMARCA4 deficient cancers.
Protocol Recommendations
Protocol Recommendations
Potential Research Applications
Potential Research Applications
Evidence For Antibody Specificity In I H C
Evidence For Antibody Specificity In I H C
